
Contemporary Pediatrics week in review: November 16-20, 2026
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
Thank you for visiting the Contemporary Pediatrics® website. Take a look at some of our top stories from last week (Monday, November 16 to Friday, November 20, 2026) and click each link to read and watch anything you may have missed.
1.) US loses measles elimination status; CDC outlines re-elimination plan
The Pan American Health Organization determined that the US no longer meets the international definition of measles elimination, a status the country had held since 2000, after concluding that transmission had continued uninterrupted for more than a year. As of mid-November, the CDC had logged over 5,400 confirmed cases for the year, more than double the 2025 total, with the large majority tied to active outbreaks. The CDC and public health partners have directed roughly $100 million to state and local health departments and are framing a return to elimination status around closing MMR vaccination gaps; kindergarten coverage has slipped from above 95% before the pandemic to under 93% more recently. Officials cautioned that no timeline or specific benchmarks were set for regaining the designation, and that measles still circulates widely abroad, leaving reinfection risk outside domestic control alone.
2.) FDA approves once-weekly somapacitan for children with Turner syndrome
The FDA approved once-weekly somapacitan-beco as the first long-acting growth hormone cleared for growth failure associated with Turner syndrome, for children 2.5 years and older. The approval draws on a 52-week trial of 105 girls randomized to weekly somapacitan or daily growth hormone injections, in which annualized height velocity came in modestly lower with the weekly option (8.9 cm/year vs 9.7 cm/year). The company points to a steep cut in injection frequency, over 300 fewer injection days a year, as the main trade-off against that small efficacy gap. Reviewers also noted the daily comparator dose used in the trial was below the maximum labeled US dose for Turner syndrome, so the study doesn't show how the weekly option stacks up against the higher daily doses some clinicians currently use.
3.) New AHA advisory calls for lifelong cardiovascular care in women
A new American Heart Association presidential advisory, developed jointly with the American Academy of Pediatrics, American College of Obstetricians and Gynecologists, and Society for Maternal-Fetal Medicine, calls for tracking women's cardiovascular risk across their entire lifespan rather than in isolated episodes of care. Pediatric and emergency physicians from Lurie Children's Hospital of Chicago explained that sex-based differences in cardiovascular health begin to emerge around puberty and are shaped by hormonal, psychosocial, and societal factors that persist through pregnancy and menopause. The experts framed pediatric and family visits as an underused opportunity to flag risk early, since women often bring both themselves and their children into the health system. The discussion builds on an earlier framework from the same four societies that set the start of cardiovascular risk assessment at perimenarche, roughly ages 8 to 15, though this piece is an expert explainer rather than new primary data, and concrete screening intervals or risk thresholds are not spelled out here.
4.) FDA approves venglustat for neurological symptoms of GD3
The FDA cleared oral venglustat as the first approved therapy aimed at the neurological symptoms of type 3 Gaucher disease, a space long-standing enzyme replacement therapy has not addressed, for patients weighing at least 15 kg. The approval rests on a phase 3 trial in patients 12 and older already stable on enzyme therapy, where venglustat outperformed continued enzyme treatment on a combined measure of ataxia and cognitive function over a year. The agency flagged serious psychiatric adverse events, including suicidal ideation, along with animal-study signals for vision effects in younger patients and fetal harm. Reviewers also noted that the trial population skewed older and was already clinically stable, so evidence directly supporting use in the youngest eligible children is limited.
5.) Tirzepatide cuts BMI 18.5% in adolescents with obesity
In the phase 3 SURMOUNT-ADOLESCENTS trial published in JAMA, once-weekly tirzepatide paired with lifestyle counseling lowered BMI by 18.5% over 72 weeks in adolescents with obesity, compared with a slight increase on placebo, and more than half of treated teens no longer met the threshold for obesity by the study's end. Gastrointestinal side effects such as vomiting, nausea, and diarrhea were common and clustered during dose increases, leading roughly 1 in 11 tirzepatide recipients to stop treatment. An accompanying editorial noted the trial population was overwhelmingly White, non-Hispanic, and already in later puberty with mostly severe obesity, meaning the results speak most directly to that group rather than to adolescents with overweight or earlier-stage puberty, and durability beyond 72 weeks is still unknown.
Related to this article








